Advancements in Alzheimer's Biomarkers Enable Early Intervention in Neurodegenerative Trials
Recent developments in Alzheimer's research have demonstrated the potential for early intervention in neurodegenerative diseases. Researchers have identified biomarkers that can signal the onset of Alzheimer's disease long before clinical symptoms appear. These include fluid biomarkers like plasma Aβ42/40 ratio, phosphorylated tau, and neurofilament light chain, as well as neuroimaging techniques such as amyloid PET imaging and volumetric MRI. Emerging technologies like optical coherence tomography are also being used to detect early neurodegenerative changes. These advancements are not just theoretical; they are being integrated into clinical trials to identify at-risk individuals earlier, allowing for more precise trial population enrichment and improved signal detection in early-stage studies. 
